AMSTERDAM, Oct. 16 -- People in Europe whose pancreatic cancer has spread and outlasted their first chemotherapy may soon have an oral pill to ask their oncologists about. On Thursday the European Medicines Agency said its human medicines committee had recommended Rasonque, known generically as daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who have had at least one earlier treatment.

The speed stands out. The agency said its review began in early July and took under 150 days, against a standard evaluation that can run up to 210 active days and usually takes about a year once company response time is counted. In August the FDA approved daraxonrasib for a similar group of patients in the United States, with Revolution ...